STOP360-IP-22
Standardizing Treatments for Pulmonary Exacerbations: A platform for evaluating treatment decisions to improve outcomes (STOP360)
- Sex: Any
- Age: Child (Birth - 17), Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase IV
- Conditions Being Studied: Lung, Cystic Fibrosis (CF)
Study Purpose
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. . This study is trying to answer the following questions about treating a pulmonary exacerbation: 1. Do participants have the same improvement in lung function and symptoms if they are treated with one type of antibiotic (called beta-lactams or ß-lactams) versus taking two different types of antibiotics (tobramycin and ß-lactams)? 2. Is taking one type of antibiotic just as good as taking two types?
Who Can Participate
Age: 6 years and older
Locations
UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: SITE00001818
- StudyID: 2022-01041
- ClinicalTrials.gov: NCT05548283
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422